EpCAM Expression in Epithelial Ovarian Cancer: Immunohistochemical and Histopathological Study | ||||
| The Medical Journal of Cairo University | ||||
| Article 14, Volume 90, Issue 3, March 2022, Page 113-119 PDF (365.4 K) | ||||
| DOI: 10.21608/mjcu.2022.234835 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| RASHA R. MOSTAFA, M.D.; MOHAMED S. NEGM, M.D.; SAMAR I. AMER, M.D. | ||||
| The Department of Pathology, Faculty of Medicine, Cairo University | ||||
| Abstract | ||||
| Abstract Background: Ovarian epithelial cancer is a dreadful gynecologic malignancy, with a usual late diagnosis and humble therapy response. EpCAM over-expression in epithelial ovarian cancer could be considered as a hopeful cancer target therapy. Aim of Study: Detection of EpCAM over-expression in ovarian cancer and correlate it with the clinic-pathological tumor features. Material and Methods: 42 paraffin blocks of ovarian cancer were immunostained with EpCAM antibody. Results: EpCAM showed high expression in 54.7% of the studied cases, and it was significantly correlated with the patients' age, tumor size, tumor grade, the presence of lym-phovascular emboli, extension to the serosal surface, and FIGO stage. Conclusion: EpCAM is overexpressed in epithelial ovarian cancer, which could be a future target therapy. | ||||
| Keywords | ||||
| EpCAM; Ovarian cancer; Prognosis | ||||
|
Statistics Article View: 199 PDF Download: 378 |
||||
